ALDR - アルダ―・バイオファ―マシュ―ティカルズ (Alder BioPharmaceuticals Inc.) アルダ―・バイオファ―マシュ―ティカルズ

 ALDRのチャート


 ALDRの企業情報

symbol ALDR
会社名 Alder Biopharmaceuticals Inc (アルダ―・バイオファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アルダー・バイオファーマシューティカルズ(Alder Biopharmaceuticals Inc.)は臨床病期のバイオ医薬品会社である。同社は現在の治療パラダイムを有効的に変革する可能性がある遺伝子操作された治療用抗体の発見・開発・商品化に従事する。同社の主要中枢段階の製品候補であるエプチネズマブは、片頭痛予防のために評価されている。エプチネズマブは、片頭痛の開始を媒介するのに活性なタンパク質であるカルシトニン遺伝子関連ペプチド(CGRP)を阻害するモノクローナル抗体である。同社はまた、片頭痛予防治療薬として開発中の前臨床製品候補であるALD1910を評価する。ALD1910は、下垂体アデニル酸シクラーゼ活性化ポリペプチド-38(PACAP-38)を阻害するモノクローナル抗体であり、片頭痛の開始を媒介する活性を有するもう一つのタンパク質である。同社の第3プログラムであるClazakizumabは、インターロイキン-6を阻害し、Vitaeris Incにライセンスされているモノクローナル抗体候補である。  アルダ―・バイオファ―マシュ―ティカルズは米国のバイオ医薬品会社。抗体の発見、開発、商品化を行う。片頭痛予防のためにカルシトニン遺伝子関連ペプチドをタ―ゲットにした単クロ―ン抗体ALD403、また、関節リウマチ治療用の炎症性サイカトンインタ―ロキシン6を阻害する単クロ―ン抗体ALD518の治験を行う。本社所在地はワシントン州。   Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.
本社所在地 11804 North Creek Parkway South Bothell WA 98011 USA
代表者氏名 Robert W. Azelby ロバート・W・アゼルバイ
代表者役職名 President Chief Executive Officer
電話番号 +1 425-205-2900
設立年月日 37377
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 193人
url www.alderbio.com
nasdaq_url https://www.nasdaq.com/symbol/aldr
adr_tso
EBITDA EBITDA(百万ドル) -263.06900
終値(lastsale) 14.2
時価総額(marketcap) 968956752.2
時価総額 時価総額(百万ドル) 15.804
売上高 売上高(百万ドル) 0.93600
企業価値(EV) 企業価値(EV)(百万ドル) 974.38700
当期純利益 当期純利益(百万ドル) -302.18700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Alder Biopharmaceuticals Inc revenues decreased from $683K to $0K. Net loss applicable to common stockholders increased 8% to $188.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General and Administrative increase of 22% to $23.8M (expense).

 ALDRのテクニカル分析


 ALDRのニュース

   All You Need to Know About Alder BioPharmaceuticals (ALDR) Rating Upgrade to Strong Buy  2019/10/15 13:00:07 Zacks Investment Research
Alder BioPharmaceuticals (ALDR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
   The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study  2019/09/17 11:23:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 16) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR )( announced a deal to be bought by Danish pharma company Lundbeck) AxsomeTherapeutics Inc (NASDAQ: AXSM ) Kodiak Sciences Inc (NASDAQ: KOD )(announced positive emerging durability data from a Phase 1b study of its pipeline asset KSI-301 in wet age-related macular degeneration) The Medicines Company (NASDAQ: MDCO ) Natera Inc (NASDAQ: NTRA ) -mAbs Therapeutics, Inc (NASDAQ: YMAB ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 16) BioNano Genomics Inc (NASDAQ: BNGO ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Myovant Sciences Ltd (NYSE: MYOV ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Acceleron To Discontinue Development Of Mid-Stage Asset To Treat Muscular Dystrophy Acceleron Pharma Inc (NASDAQ: XLRN ) said it's halting the development of ACE-083 as a treatment option for patients with facioscapulohumeral muscular dystrophy.
   Danish Company To Buy Migraine Drug Developer Alder Biopharma In Deal Worth Up To $1.95B  2019/09/16 13:19:43 Benzinga
Merger Monday dawned with Danish pharma company Lundbeck announcing a definitive agreement to buy U.S.-based Alder Biopharmaceuticals Inc (NASDAQ: ALDR ). The Deal Terms Alder shareholders will receive $18 per share in cash as part of the deal, along with one tradeable contingent value right that entitles them to receive an additional $2 per share upon approval of eptinezumab — a Phase 3 migraine prevention drug candidate — by the European Medicines Agency. This renders the total consideration to $20 per share, with a total transaction value of $1.95 billion net of cash on a fully diluted basis. The upfront cash payment of $18 per share represents a 79% premium to the Sept. 13 closing price of Alder shares . The boards of both companies have approved the transaction. The proposed deal is expected to close in the fourth quarter of 2019, subject to customary closing conditions, including tendering of more than 50% of Alder shares at … Full story available on Benzinga.com
   The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved  2019/08/28 11:31:33 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) Castle Biosciences Inc (NASDAQ: CSTL ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 27) Abeona Therapeutics Inc (NASDAQ: ABEO ) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alimera Sciences Inc (NASDAQ: ALIM ) AnaptysBio Inc (NASDAQ: ANAB ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Assembly Biosciences Inc (NASDAQ: ASMB ) Cancer Genetics Inc (NASDAQ: CGIX ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Clearside Biomedical Inc (NASDAQ: CLSD ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced that its current cash position will be sufficient to complete enrollment in all three patient groups of its two ongoing Phase 2 trials for its lead compound VAL-083, which is likely to occur by the fourth quarter of 2020) ICU Medical, Incorporated (NASDAQ: ICUI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Mallinckrodt PLC (NYSE: MNK )(reacted to an unfavorable ruling on a patent infringement lawsuit regarding its inhaled nitric oxide product) Neuralstem, Inc. (NASDAQ: CUR ) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Regenxbio Inc (NASDAQ: RGNX ) Revance Therapeutics Inc (NASDAQ: RVNC )(announced an amended agreement with Mylan NV (NASDAQ: MYL ), …
   The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering  2019/08/06 11:22:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.
   All You Need to Know About Alder BioPharmaceuticals (ALDR) Rating Upgrade to Strong Buy  2019/10/15 13:00:07 Zacks Investment Research
Alder BioPharmaceuticals (ALDR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
   The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study  2019/09/17 11:23:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 16) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR )( announced a deal to be bought by Danish pharma company Lundbeck) AxsomeTherapeutics Inc (NASDAQ: AXSM ) Kodiak Sciences Inc (NASDAQ: KOD )(announced positive emerging durability data from a Phase 1b study of its pipeline asset KSI-301 in wet age-related macular degeneration) The Medicines Company (NASDAQ: MDCO ) Natera Inc (NASDAQ: NTRA ) -mAbs Therapeutics, Inc (NASDAQ: YMAB ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 16) BioNano Genomics Inc (NASDAQ: BNGO ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Myovant Sciences Ltd (NYSE: MYOV ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Acceleron To Discontinue Development Of Mid-Stage Asset To Treat Muscular Dystrophy Acceleron Pharma Inc (NASDAQ: XLRN ) said it's halting the development of ACE-083 as a treatment option for patients with facioscapulohumeral muscular dystrophy.
   Danish Company To Buy Migraine Drug Developer Alder Biopharma In Deal Worth Up To $1.95B  2019/09/16 13:19:43 Benzinga
Merger Monday dawned with Danish pharma company Lundbeck announcing a definitive agreement to buy U.S.-based Alder Biopharmaceuticals Inc (NASDAQ: ALDR ). The Deal Terms Alder shareholders will receive $18 per share in cash as part of the deal, along with one tradeable contingent value right that entitles them to receive an additional $2 per share upon approval of eptinezumab — a Phase 3 migraine prevention drug candidate — by the European Medicines Agency. This renders the total consideration to $20 per share, with a total transaction value of $1.95 billion net of cash on a fully diluted basis. The upfront cash payment of $18 per share represents a 79% premium to the Sept. 13 closing price of Alder shares . The boards of both companies have approved the transaction. The proposed deal is expected to close in the fourth quarter of 2019, subject to customary closing conditions, including tendering of more than 50% of Alder shares at … Full story available on Benzinga.com
   The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved  2019/08/28 11:31:33 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) Castle Biosciences Inc (NASDAQ: CSTL ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 27) Abeona Therapeutics Inc (NASDAQ: ABEO ) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alimera Sciences Inc (NASDAQ: ALIM ) AnaptysBio Inc (NASDAQ: ANAB ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Assembly Biosciences Inc (NASDAQ: ASMB ) Cancer Genetics Inc (NASDAQ: CGIX ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Clearside Biomedical Inc (NASDAQ: CLSD ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced that its current cash position will be sufficient to complete enrollment in all three patient groups of its two ongoing Phase 2 trials for its lead compound VAL-083, which is likely to occur by the fourth quarter of 2020) ICU Medical, Incorporated (NASDAQ: ICUI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Mallinckrodt PLC (NYSE: MNK )(reacted to an unfavorable ruling on a patent infringement lawsuit regarding its inhaled nitric oxide product) Neuralstem, Inc. (NASDAQ: CUR ) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Regenxbio Inc (NASDAQ: RGNX ) Revance Therapeutics Inc (NASDAQ: RVNC )(announced an amended agreement with Mylan NV (NASDAQ: MYL ), …
   The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering  2019/08/06 11:22:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.
   All You Need to Know About Alder BioPharmaceuticals (ALDR) Rating Upgrade to Strong Buy  2019/10/15 13:00:07 Zacks Investment Research
Alder BioPharmaceuticals (ALDR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
   The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study  2019/09/17 11:23:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 16) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR )( announced a deal to be bought by Danish pharma company Lundbeck) AxsomeTherapeutics Inc (NASDAQ: AXSM ) Kodiak Sciences Inc (NASDAQ: KOD )(announced positive emerging durability data from a Phase 1b study of its pipeline asset KSI-301 in wet age-related macular degeneration) The Medicines Company (NASDAQ: MDCO ) Natera Inc (NASDAQ: NTRA ) -mAbs Therapeutics, Inc (NASDAQ: YMAB ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 16) BioNano Genomics Inc (NASDAQ: BNGO ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Myovant Sciences Ltd (NYSE: MYOV ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Acceleron To Discontinue Development Of Mid-Stage Asset To Treat Muscular Dystrophy Acceleron Pharma Inc (NASDAQ: XLRN ) said it's halting the development of ACE-083 as a treatment option for patients with facioscapulohumeral muscular dystrophy.
   Danish Company To Buy Migraine Drug Developer Alder Biopharma In Deal Worth Up To $1.95B  2019/09/16 13:19:43 Benzinga
Merger Monday dawned with Danish pharma company Lundbeck announcing a definitive agreement to buy U.S.-based Alder Biopharmaceuticals Inc (NASDAQ: ALDR ). The Deal Terms Alder shareholders will receive $18 per share in cash as part of the deal, along with one tradeable contingent value right that entitles them to receive an additional $2 per share upon approval of eptinezumab — a Phase 3 migraine prevention drug candidate — by the European Medicines Agency. This renders the total consideration to $20 per share, with a total transaction value of $1.95 billion net of cash on a fully diluted basis. The upfront cash payment of $18 per share represents a 79% premium to the Sept. 13 closing price of Alder shares . The boards of both companies have approved the transaction. The proposed deal is expected to close in the fourth quarter of 2019, subject to customary closing conditions, including tendering of more than 50% of Alder shares at … Full story available on Benzinga.com
   The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved  2019/08/28 11:31:33 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) Castle Biosciences Inc (NASDAQ: CSTL ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 27) Abeona Therapeutics Inc (NASDAQ: ABEO ) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alimera Sciences Inc (NASDAQ: ALIM ) AnaptysBio Inc (NASDAQ: ANAB ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Assembly Biosciences Inc (NASDAQ: ASMB ) Cancer Genetics Inc (NASDAQ: CGIX ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Clearside Biomedical Inc (NASDAQ: CLSD ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced that its current cash position will be sufficient to complete enrollment in all three patient groups of its two ongoing Phase 2 trials for its lead compound VAL-083, which is likely to occur by the fourth quarter of 2020) ICU Medical, Incorporated (NASDAQ: ICUI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Mallinckrodt PLC (NYSE: MNK )(reacted to an unfavorable ruling on a patent infringement lawsuit regarding its inhaled nitric oxide product) Neuralstem, Inc. (NASDAQ: CUR ) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Regenxbio Inc (NASDAQ: RGNX ) Revance Therapeutics Inc (NASDAQ: RVNC )(announced an amended agreement with Mylan NV (NASDAQ: MYL ), …
   The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering  2019/08/06 11:22:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アルダ―・バイオファ―マシュ―ティカルズ ALDR Alder BioPharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)